Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

lutetium Lu 177 LNC1004

A radioconjugate consisting of an Evans blue (EB) modified fibroblast activation protein inhibitor (FAPi), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecane tetraacetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration of lutetium Lu 177 LNC1004, the FAPi moiety targets and binds to FAP-expressing cancer-associated fibroblasts (CAFs). Upon binding and internalization, the radioconjugate specifically delivers a cytotoxic dose of beta radiation to FAP-expressing CAFs. FAP, a cell surface protein, is overexpressed on CAFs in the tumor microenvironment (TME).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:177Lu-LNC1004
lutetium Lu 177-LNC1004
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search